155 related articles for article (PubMed ID: 23449477)
1. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Aliabadi HM; Mahdipoor P; Uludağ H
Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
Montazeri Aliabadi H; Landry B; Mahdipoor P; Uludağ H
Mol Pharm; 2011 Oct; 8(5):1821-30. PubMed ID: 21838308
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
5. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
6. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.
Aliabadi HM; Maranchuk R; Kucharski C; Mahdipoor P; Hugh J; Uludağ H
J Control Release; 2013 Nov; 172(1):219-228. PubMed ID: 23994345
[TBL] [Abstract][Full Text] [Related]
7. Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery.
Thapa B; Bahadur Kc R; Uludağ H
Int J Cancer; 2018 Feb; 142(3):597-606. PubMed ID: 28960310
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat.
Cheng D; Cao N; Chen J; Yu X; Shuai X
Biomaterials; 2012 Feb; 33(4):1170-9. PubMed ID: 22061491
[TBL] [Abstract][Full Text] [Related]
9. Silencing of myeloid cell leukemia-1 by small interfering RNA improves chemosensitivity to etoposide in u-937 leukemic cells.
Jafarlou M; Baradaran B; Shanehbandi D; Saedi TA; Jafarlou V; Karimi P; Othman F
J Biol Regul Homeost Agents; 2016; 30(1):55-65. PubMed ID: 27049076
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.
Oh B; Park S; Pak JH; Kim I
Biochem Biophys Res Commun; 2012 May; 422(1):42-7. PubMed ID: 22554523
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia.
Jafarlou M; Shanehbandi D; Dehghan P; Mansoori B; Othman F; Baradaran B
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1792-1798. PubMed ID: 29113504
[TBL] [Abstract][Full Text] [Related]
13. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
14. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Moriai R; Tsuji N; Moriai M; Kobayashi D; Watanabe N
Breast Cancer Res Treat; 2009 Sep; 117(2):261-71. PubMed ID: 18815881
[TBL] [Abstract][Full Text] [Related]
15. [The effects of Mcl-1 gene on ATRA-resistant HL-60 cell].
Fu JR; Liu WL; Zhou JF; Sun HY; Zheng M; Huang M; Li CR; Ran D; Luo L
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):352-4. PubMed ID: 16185481
[TBL] [Abstract][Full Text] [Related]
16. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
Abbasi M; Lavasanifar A; Uludag H
Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.
Navarro G; Sawant RR; Biswas S; Essex S; Tros de Ilarduya C; Torchilin VP
Nanomedicine (Lond); 2012 Jan; 7(1):65-78. PubMed ID: 22191778
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
19. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
20. [RNAi-mediated gene silencing of livin synergistic with epirubicin enhance apoptosis of human breast cancer cells].
Liang CY; Ma P; Liu XL
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1703-6. PubMed ID: 19024543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
